Brought to you by 
J&J signs influenza deal, buys 18% of Crucell for $443mm
Oct 2009
Executive Summary
Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals (OMJP) will work with Crucell NV (developing vaccines, proteins, and antibodies for infectious diseases) on the discovery, development, and marketing of monoclonal antibodies and vaccines to prevent and treat influenza and other diseases.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J signs influenza deal, buys 18% of Crucell for $443mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice